Alzamend's 'Smarter Lithium' Shows Promise in Brain Disease Fight

ATLANTA, GA – March 26, 2026 – Clinical-stage biopharmaceutical company Alzamend Neuro today announced encouraging results from a clinical trial that could represent a significant step forward in treating a range of debilitating neurological and psychiatric conditions. The company's novel drug candidate, AL001, demonstrated in a Phase II study that it can deliver more lithium to the brain, and do so faster, than the standard treatment, while maintaining equivalent safety levels in the bloodstream.

These findings, stemming from the first part of a multi-trial program, suggest AL001 could one day offer a safer and more effective option for the millions of people affected by Alzheimer's disease, bipolar disorder, major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). The study confirmed that AL001 meets the FDA's bioequivalence standards—a key regulatory hurdle—while showing superior performance in delivering its therapeutic payload directly to the target organ: the brain.

A Potential Breakthrough for a Decades-Old Treatment

Lithium has been a cornerstone treatment for bipolar disorder for over half a century, valued for its mood-stabilizing properties. However, its use has always been a delicate balancing act. The drug is notorious for its narrow therapeutic window, meaning the dose required for effectiveness is perilously close to a dose that can cause toxic side effects. Patients on traditional lithium carbonate must undergo frequent blood monitoring to avoid dangerous complications affecting the kidneys, thyroid, and nervous system.

Alzamend's AL001 is designed to overcome these long-standing challenges. It is a patented ionic cocrystal formulation that combines lithium with L-proline and salicylate, engineered to enhance its ability to cross the blood-brain barrier. The goal is to achieve a therapeutic effect in the brain using a lower overall dose, thereby reducing the drug's impact on the rest of the body and mitigating the risk of toxicity.

The recent Phase II data provides the first clinical evidence that this 'smarter lithium' approach may work as intended. The study showed AL001 delivered 101% of the total lithium to the bloodstream compared to standard lithium carbonate, meeting the FDA's requirement for a new formulation to be considered equally safe systemically.

"These data mark a pivotal advancement in the development of AL001," said Stephan Jackman, CEO of Alzamend, in a statement. "We have clinical evidence that AL001 shows equivalent delivery of lithium in the bloodstream compared to standard lithium carbonate capsules, which is a key regulatory safety measure. And the brain data, while preliminary, show a consistent increase providing higher lithium in every brain region we measured. This can permit lower systemic doses to achieve efficacy thereby providing an enhanced safety profile."

A Glimpse Inside the Brain with Advanced Imaging

The 'Lithium in Brain' study, conducted at the prestigious Massachusetts General Hospital (MGH), employed a first-of-its-kind methodology to achieve its results. Researchers used a specialized, high-powered head coil developed by Tesla Dynamic Coils BV in conjunction with advanced magnetic resonance imaging (MRI) and spectroscopy (MRS) techniques.

This cutting-edge approach, developed in the lab of principal investigator Dr. Ovidiu Andronesi of Harvard Medical School and MGH, allowed for the precise quantification of lithium levels in 26 distinct regions of the brain simultaneously with blood-level measurements. This provided an unprecedentedly detailed picture of how both AL001 and standard lithium are processed by the body and brain.

The results were compelling. Compared to standard lithium carbonate, AL001 demonstrated numerically higher lithium concentrations in every single brain region measured. This included critical areas like the hippocampus (memory), entorhinal cortex (an early target of Alzheimer's), and cingulate gyrus (cognition). Overall, the maximum whole-brain lithium exposure saw a nearly 8% increase with AL001.

Furthermore, AL001 reached its peak concentration in the brain significantly faster, clocking in at 6.7 hours compared to 8.4 hours for the standard formulation. This 1.7-hour advantage could have important implications for how quickly the drug begins to take effect and how dosing schedules are optimized for patients.

The Road Ahead: Navigating Clinical and Financial Hurdles

While the topline data from this initial cohort of healthy volunteers is promising, Alzamend acknowledges it is a first step. The initial sample size of six subjects per arm is considered directionally meaningful but not yet statistically definitive. To build a more robust case, the company has already embarked on the next stage of its clinical program.

A second Phase II trial, this time enrolling patients with bipolar disorder, is already underway at MGH, with topline data anticipated in the third quarter of 2026. This will be the first test of AL001 in a target patient population. Alzamend plans to follow this with three more studies in patients with MDD, PTSD, and Alzheimer's disease, respectively.

However, the company has noted that the initiation of these subsequent trials, planned for the latter half of 2026, is "subject to raising sufficient capital." This is a common and critical reality for clinical-stage biotechnology firms, which often rely on positive data to attract the significant investment needed to fund late-stage research and development. The company's future progress is therefore contingent on both continued clinical success and its ability to secure financial backing in a competitive market.

Should AL001 continue to prove its value, the potential impact is enormous. A safer, better-tolerated lithium could revolutionize treatment for the more than 43 million Americans that Alzamend estimates are afflicted with these four target conditions. For patients who struggle with the side effects and rigorous monitoring of current lithium therapy, or for whom it is not a viable option, AL001 could represent a long-awaited breakthrough, transforming the standard of care and improving quality of life.